𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Squamous cell carcinoma of the head and neck in solid organ transplant recipients

✍ Scribed by Diego A. Preciado; Arthur Matas; George L. Adams


Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
149 KB
Volume
24
Category
Article
ISSN
1043-3074

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Background

The increased incidence of cancer after solid organ transplantation is well established in the literature, yet outcome studies in this population are rare. Excluding skin cancers, squamous cell carcinomas make up most head and neck cancers in transplant recipients.

Methods

At our institution, of 5300 solid organ transplant recipients, 34 have had head and neck cancer develop. We reviewed the records of the 23 recipients whose cancer was treated here.

Results

Only 6 of the 23 recipients were alive at the time of our chart review. Of these, three had already survived 5 years. The 10 recipients diagnosed early (stage I or II) had significantly longer survival after cancer diagnosis than the 13 diagnosed at an advanced stage (stage III or IV) (96.0 mo vs 9.0 mo, p < .001). In all, 14 (60.8%) of the 23 recipients died of cancer within 2 years after diagnosis, 12 (50.2%) within 12 months. The sum of the daily doses of immunosuppressive drugs at cancer diagnosis was significantly greater for recipients who died within 2 years (p = .02). Furthermore, the difference in average doses of both prednisone (p = .001) and azathioprine (p = .028) was also significantly greater for those who died within 2 years. The average dose of cyclosporine was also greater, but this difference did not reach statistical significance (p = .18). The average dose of prednisone was significantly lower for recipients diagnosed early (p = .001). This correlation between high immunosuppressive drug doses and worse outcome has not been shown previously.

Conclusions

Solid organ transplant recipients who are diagnosed with advanced head and neck cancer while receiving high doses of immunosuppressive drugs fare extremely poorly. High doses of immunosuppressive drugs, most notably prednisone, correlate significantly with advanced diagnosis of head and neck cancer and earlier death. Β© 2002 Wiley Periodicals, Inc. Head Neck 24: 319–325, 2002; DOI 10.1002/hed.10055


πŸ“œ SIMILAR VOLUMES


Head and neck squamous cell carcinoma in
✍ de Carvalho, Marcos Brasilino; Sobrinho, Josias de Andrade; Rapoport, AbrΓ£o; Fav πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 103 KB πŸ‘ 2 views

## Background: Squamous cell carcinoma (scc) of the head and neck region is rare in young patients and even less frequent in children 15 years or younger children. the patients reported in the literature are isolated cases and their management is always difficult because there is no large experienc

Head and neck squamous cell carcinoma in
✍ Vladimir Vinarsky; Robert L. Fine; Adel Assaad; Ying Qian; John A. Chabot; Glori πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 364 KB πŸ‘ 2 views

## Abstract ## Background Germline mutations at the __INK4a/p16__ locus are implicated in several human cancer syndromes, including familial atypical multiple mole melanoma (FAMMM) syndrome, FAMMM‐pancreatic cancer (FAMMM‐PC) syndrome, and in familial head and neck cancer syndrome. ## Methods We

MicroRNA alterations in head and neck sq
✍ Steven S. Chang; Wei Wen Jiang; Ian Smith; Luana M. Poeta; Shahnaz Begum; Chad G πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 French βš– 244 KB πŸ‘ 1 views

## Abstract MicroRNAs (mirs) are small noncoding RNA molecules (∼22 nucleotides) that regulate posttranscriptional gene expression. Currently, there has not been a comprehensive study of their role in primary head and neck squamous cell carcinoma (HNSCC). To determine the role of mirs in HNSCC, we

Targeted therapies in squamous cell carc
✍ Kathryn A. Gold; Ho-Young Lee; Edward S. Kim πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 170 KB πŸ‘ 3 views

## Abstract Head and neck cancer is a challenging disease that is expected to account for greater than 500,000 new cases worldwide in 2008. Toxicity has impeded advances in chemotherapy and radiation for head and neck cancer, and the prognosis for patients with recurrent and/or metastatic disease r

Efficacy of neck treatment in patients w
✍ Gabriela Buck; Pia Huguenin; Sandro J. Stoeckli πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 2 views

## Abstract ## Background. Treatment of head and neck squamous cell carcinoma (HNSCC) addresses the primary tumor and the lymphatic drainage. Modalities for the neck are neck dissection and/or radiation therapy. In most cases, the neck is treated by the modality that seems more appropriate for the